Nanoparticles for the delivery of genes and drugs to human hepatocytes

被引:211
作者
Yamada, T
Iwasaki, Y
Tada, H
Iwabuki, H
Chuah, MKL
VandenDriessche, T
Fukuda, H
Kondo, A
Ueda, M
Seno, M
Tanizawa, K
Kuroda, S
机构
[1] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan
[2] Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan
[3] Keio Univ, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan
[4] Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan
[5] JST, Chiyoda Ku, Tokyo 1028666, Japan
[6] Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium
[7] Kobe Univ, Fac Engn, Nada Ku, Kobe, Hyogo 6578501, Japan
[8] Beacle Inc, Okayama 7038273, Japan
关键词
D O I
10.1038/nbt843
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Hepatitis B virus envelope L particles form hollow nanoparticles displaying a peptide that is indispensable for liver-specific infection by hepatitis B virus in humans. Here we demonstrate the use of L particles for the efficient and specific transfer of a gene or drug into human hepatocytes both in culture and in a mouse xenograft model. In this model, intravenous injection of L particles carrying the gene for green fluorescent protein (GFP) or a fluorescent dye resulted in observable fluorescence only in human hepatocellular carcinomas but not in other human carcinomas or in mouse tissues. When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes. These advantages should facilitate targeted delivery of genes and drugs to the human liver.
引用
收藏
页码:885 / 890
页数:6
相关论文
共 35 条
[1]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[2]   Gene therapy for SCID - a complication after remarkable progress [J].
Buckley, RH .
LANCET, 2002, 360 (9341) :1185-1186
[3]   VACCINE-INDUCED ESCAPE MUTANT OF HEPATITIS-B VIRUS [J].
CARMAN, WF ;
ZANETTI, AR ;
KARAYIANNIS, P ;
WATERS, J ;
MANZILLO, G ;
TANZI, E ;
ZUCKERMAN, AJ ;
THOMAS, HC .
LANCET, 1990, 336 (8711) :325-329
[4]   Altered antigenicity of 'a' determinant variants of hepatitis B virus [J].
Chiou, HL ;
Lee, TS ;
Kuo, J ;
Mau, YC ;
Ho, MS .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :2639-2645
[5]   Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors [J].
Chuah, MKL ;
Schiedner, G ;
Thorrez, L ;
Brown, B ;
Johnston, M ;
Gillijns, V ;
Hertel, S ;
Van Rooijen, N ;
Lillicrap, D ;
Collen, D ;
VandenDriessche, T ;
Kochanek, S .
BLOOD, 2003, 101 (05) :1734-1743
[6]  
Chuah MKL, 2001, J GENE MED, V3, P3, DOI 10.1002/1521-2254(200101/02)3:1<3::AID-JGM167>3.0.CO
[7]  
2-H
[8]   Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity [J].
delCanho, R ;
Grosheide, PM ;
Mazel, JA ;
Heijtink, RA ;
Hop, WCJ ;
Gerards, LJ ;
deGast, GC ;
Fetter, WPF ;
Zwijneberg, J ;
Schalm, SW .
VACCINE, 1997, 15 (15) :1624-1630
[9]   Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors [J].
Follenzi, A ;
Sabatino, G ;
Lombardo, A ;
Boccaccio, C ;
Naldini, L .
HUMAN GENE THERAPY, 2002, 13 (02) :243-260
[10]   Investigation of gene therapy begins [J].
Fox, JL .
NATURE BIOTECHNOLOGY, 2000, 18 (02) :143-144